JTC Employer Solutions Trustee Ltd Sells 202,398 Shares of GSK plc (NYSE:GSK)

JTC Employer Solutions Trustee Ltd lessened its position in GSK plc (NYSE:GSK) by 1.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 20,278,564 shares of the pharmaceutical company’s stock after selling 202,398 shares during the period. GSK comprises approximately 48.3% of JTC Employer Solutions Trustee Ltd’s holdings, making the stock its biggest holding. JTC Employer Solutions Trustee Ltd owned about 0.98% of GSK worth $682,272,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Eastern Bank acquired a new position in shares of GSK during the third quarter worth approximately $26,000. ST Germain D J Co. Inc. lifted its position in GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 522 shares during the period. Sunbelt Securities Inc. boosted its stake in shares of GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares during the last quarter. Concord Wealth Partners boosted its stake in GSK by 231.8% in the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after acquiring an additional 547 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC bought a new position in GSK during the second quarter worth about $37,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on GSK. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and cut their price target for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Finally, StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Monday. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Price Performance

Shares of NYSE GSK traded down $0.45 during midday trading on Monday, reaching $32.64. 2,359,896 shares of the company were exchanged, compared to its average volume of 2,857,900. The stock’s 50-day moving average price is $34.38 and its 200-day moving average price is $38.17. The stock has a market cap of $67.65 billion, a P/E ratio of 21.19, a PEG ratio of 1.52 and a beta of 0.63. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. GSK plc has a one year low of $32.55 and a one year high of $45.92.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, January 9th. Shareholders of record on Friday, November 15th were given a $0.3928 dividend. The ex-dividend date of this dividend was Friday, November 15th. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a yield of 4.81%. GSK’s dividend payout ratio (DPR) is currently 95.45%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.